** Shares of biotech firm Creative Medical Technology Holdings CELZ.O rise 16.1% to $5.33 premarket
** Co says its mid-term follow-up data showed its stem cell therapy, called StemSpine, was successful in treating chronic lower back pain and reducing opioid dependency
** Says the study shows significant improvements in pain levels and functional mobility
** Says no serious adverse events were reported
** Over 90% of patients reported no opioid use for pain management three years post-procedure, co says
** CELZ rose ~9% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。